Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers

Abstract Nilotinib, a second‐generation tyrosine kinase inhibitor (TKI), has been approved in the United States and Europe as a treatment for patients with newly diagnosed chronic myeloid leukemia (CML)‐chronic phase (CP) and patients with CML‐CP or chronic myeloid leukemia‐accelerated phase (CML‐AP) who are resistant or intolerant to imatinib (a first‐generation TKI). This study compared the bioequivalence and safety of the test nilotinib capsule and reference nilotinib capsule (Tasigna, Novartis) in healthy Chinese volunteers under fasting conditions for marketing authorization in China. The results of the study are reported for the first time. This was a single‐dose, randomized, open‐label, two‐period, and cross‐over study. Thirty healthy volunteers were randomly assigned to receive a single dose of a 200‐mg test or reference capsule under fasting conditions in each period with a 10‐day washout. Plasma samples were analyzed with liquid chromatography‐tandem mass spectrometry. Pharmacokinetic parameters were calculated with WinNonlin software. The geometric mean ratio and the corresponding 90% confidence intervals of C max , AUC 0‐t , and AUC 0‐∞ for nilotinib between the two fixed‐dose combination formulations were within the bioequivalence acceptance range of 80%–125%, therefore the generic and branded formulations were bioequivalent in healthy Chinese volunteers.